Downregulation of peripheral luteinizing hormone rescues ovariectomy-associated cognitive deficits in APP/PS1 mice

Neurobiol Aging. 2024 Mar:135:60-69. doi: 10.1016/j.neurobiolaging.2023.12.007. Epub 2023 Dec 31.

Abstract

Alzheimer's disease (AD) is more prevalent in women than men, supposing due to the decline of estrogens in menopause, accompanied by increased gonadotropins such as luteinizing hormone (LH). We and others found that the transcription factor early growth response-1 (EGR1) regulates cholinergic function including the expression of acetylcholinesterase (AChE) and plays a significant role in cognitive decline of AD. Here we investigated in APP/PS1 mice by ovariectomy (OVX) and estradiol (E2) supplementation or inhibition of LH the effect on hippocampus-related cognition and related molecular changes. We found that OVX-associated cognitive impairment was accompanied by increased dorsal hippocampal EGR1 expression, which was rescued by downregulating peripheral LH rather than by supplementing E2. We also found in postmortem AD brains a higher expression of pituitary LH-mRNA and higher EGR1 expression in the posterior hippocampus. Both, in human and mice, there was a significant positive correlation between respectively posterior/dorsal hippocampal EGR1 and peripheral LH expression. We conclude that peripheral increased LH and increased posterior hippocampal EGR1 plays a significant role in AD pathology.

Keywords: Alzheimer’s disease; Early growth response-1; Estrogen; Hippocampus; Luteinizing hormone; β-Amyloid.

MeSH terms

  • Acetylcholinesterase
  • Alzheimer Disease* / metabolism
  • Animals
  • Cognition
  • Cognitive Dysfunction* / genetics
  • Cognitive Dysfunction* / metabolism
  • Disease Models, Animal
  • Down-Regulation
  • Female
  • Hippocampus / metabolism
  • Humans
  • Luteinizing Hormone / metabolism
  • Mice
  • Mice, Transgenic
  • Ovariectomy

Substances

  • Luteinizing Hormone
  • Acetylcholinesterase